SVOBODA, Marek, Jiří ŠÁNA, Pavel FABIAN, Ilona KOCÁKOVÁ, Jana GOMBOŠOVÁ, Jana NEKVINDOVÁ, Lenka RADOVÁ, Rostislav VYZULA a Ondřej SLABÝ. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiation Oncology. roč. 7, č. 1, s. 195. ISSN 1748-717X. 2012.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Autoři SVOBODA, Marek, Jiří ŠÁNA, Pavel FABIAN, Ilona KOCÁKOVÁ, Jana GOMBOŠOVÁ, Jana NEKVINDOVÁ, Lenka RADOVÁ, Rostislav VYZULA a Ondřej SLABÝ.
Vydání Radiation Oncology, 2012, 1748-717X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.107
Organizační jednotka Lékařská fakulta
UT WoS 000312861600002
Klíčová slova anglicky MicroRNAs; oncology; chemoradiotherapy; predictive markers
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 15. 10. 2015 13:05.
Anotace
BACKGROUND: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. Expression levels of 8 miRNAs significantly differed between two groups. MiR-215, miR-190b and miR-29b-2* have been overexpressed in non-responders, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a* have shown higher expression levels in responders. Using these miRNAs 9 of 10 responders and 9 of 10 non-responders (p < 0.05) have been correctly classified. Our pilot study suggests that miRNAs are part of the mechanisms that are involved in response of rectal cancer to the chemoradiotherapy and that miRNAs may be promising predictive biomarkers for such patients. In most miRNAs we identified (miR-215, miR-99a*, miR-196b, miR-450b-5p and let-7e), the connection between their expression and radioresistance or chemoresistance to inhibitors of thymidylate synthetase was already established.
VytisknoutZobrazeno: 16. 4. 2024 20:19